Connection

David Koch to Neovascularization, Pathologic

Back to Details
This is a "connection" page, showing publications David Koch has written about Neovascularization, Pathologic.
David Koch
Connection Strength
0.149
Neovascularization, Pathologic
  1. Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver Transpl. 2019 08; 25(8):1155-1164.
    View in: PubMed
    Score: 0.149
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.